MétaCan
Menu
← Back to cohort
Record W1923449590 · doi:10.4212/cjhp.v55i2.550

Treating Genetic Disease

2002· article· en· W1923449590 on OpenAlexvenueno aff
Scott Walker

Bibliographic record

VenueThe Canadian Journal of Hospital Pharmacy · 2002
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBRCA gene mutations in cancer
Canadian institutionsnot available
Fundersnot available
KeywordsDiseaseCancerBreast cancerMedicineColorectal cancerGenetic counselingOvarian cancerPancreatic cancerCancer syndromeOncologyGeneticsBioinformaticsGeneMutationInternal medicineBiologyGermline mutation

Abstract

fetched live from OpenAlex

Colon cancer, specifically hereditary nonpolyposis colorectal cancer, and breast cancer are malignant diseases that show some degree of genetic inheritance, as do cystic fibrosis, Duchenne muscular dystrophy, and neurofibromatosis. In fact, humans are afflicted by nearly 4000 genetic diseases, and the possibility exists that knowledge of a person’s genetic code could allow us to prevent or cure some of them. Cancers arise from a multistep process involving the interplay of multiple changes, or mutations, in several different genes, in combination with environmental factors such as diet or lifestyle. In the most common, noninherited forms of cancer, the genetic changes are acquired after birth. But people who have a hereditary risk for cancer are born with one or more altered genes — in other words, they are one step along the road to cancer from birth. Women in general have a 10% risk of breast cancer and a 2% to 3% chance of ovarian cancer sometime in their lifetime. With regard to breast cancer, mutations in the BRCA-1 and BRCA-2 genes are present in only a small portion (5% to 10%) of all cases, but carriers of mutations in these genes have a greater risk of cancer, especially before menopause. Similarly, in hereditary nonpolyposis colorectal cancer, children who inherit an altered gene from either parent face a 70% to 80% chance of developing this disease, usually at an early age. In treating a genetic disease, the first question that must be answered is, Which altered gene causes the disease? Two related questions are, What protein does this gene normally produce? and Can the altered protein or gene be fixed or replaced? Determining the answer to the first question is often difficult, because few clues exist as to where, on any of the 23 pairs of chromosomes, the altered gene resides. However, as a result of the Human Genome Project, the altered genes for many genetic diseases have now been identified. These discoveries offer a preview of how the Human Genome Project is likely to transform medicine by opening up new approaches to prevention. The earliest beneficiaries will be individuals and families who face a very high risk of cancer. First, for those who choose to take it, will come a simple blood test to determine if they carry the altered gene or genes. In the case of hereditary nonpolyposis colorectal cancer, individuals found to carry an altered gene would likely receive counselling to adopt a high-fibre, low-fat diet in the hope of preventing the cancer. They would also be advised to undergo yearly colon examinations starting at about age 30. Such exams should help to detect any Treating Genetic Disease

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.007
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.037
Threshold uncertainty score0.125

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.007
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0010.001
Scholarly communication0.0020.002
Open science0.0010.002
Research integrity0.0040.005
Insufficient payload (model declined to judge)0.0370.015

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.016
GPT teacher head0.262
Teacher spread0.246 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2002
Admission routes1
Has abstractyes

Explore more

Same venueThe Canadian Journal of Hospital Pharmacy→Same topicBRCA gene mutations in cancer→French-language works237,207→